semaj83/ctmatch_classification huggingface dataset:
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stroke Endovascular Therapy Clinical signs and symptoms consistent with the diagnosis of an acute ischemic stroke 2. Age ≥18 years 3. NIHSS ≥ 6 4. ICA or MCA-M1 or MCA-M2 occlusion as evidenced by MRA or 4D-CTA 5. Ethrombectomy can be initiated (femoral puncture) within 6 hours after onset or between 6 and 24 hours after time last know well if conform to the imaging Target Mismatch Profile on CT perfusion or MR perfusion: ischemic core volume is ≤ 70 ml, mismatch ratio is ≥ 1.8, penumbra volume is ≥ 15 ml  Large area cerebral infarction of anterior circulation on early CT image (more than 1/3 of cerebral hemisphere) 2. Blood glucose <2.7mmol/L or >22.2mmol/L 3. Other serious, advanced, or terminal illness (investigator judgment) or life expectancy is less than 90 days 4. Pregnant
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Stroke, Complication Stroke Stroke Sequelae Hemiparesis Arm Paralysis Must be 18 years or older Clinical diagnosis of stroke (hemorrhagic or ischemic, cortical or subcortical), confirmed by brain computer tomography or magnetic resonance imaging, that occurred six or more months prior to enrollment Must have arm weakness due to stroke Participant is willing to comply with all follow-up evaluations at the specified times Participant is able to provide informed consent prior to enrollment in the study The participant is fluent in English > 24 on the Mini Mental Status Examination Medically stable Passive flexion of shoulder in weakened upper extremity with range of > 30 degrees or more Passive abduction of shoulder in weakened upper extremity with range of > 20 degrees or more  No medical condition requiring active anti-coagulation with a medication such as heparin, warfarin or rivaroxaban (note that anti-platelet agents such as aspirin or clopidogrel are acceptable) No active wound healing or skin breakdown issues No history of poorly controlled autonomic dysreflexia Visual impairment such that extended viewing of a computer monitor would be challenging even with ordinary corrective lenses Chronic oral or intravenous steroids or immunosuppressive therapy A score of 23 or lower on Folstein's Mini-Mental Status Examination Orthopedic conditions of either arm that would affect performance on study Untreated psychiatric disturbances that would affect motivation and trial participation Medical contraindications for general anesthesia, craniotomy, or surgery Diagnosis of acute myocardial infarction or cardiac arrest within previous 6 months
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 19.0-85.0,  Muscle Spasticity Physiology Ischemic / hemorrhagic poststroke hemiplegia 2. Stroke time ≥1 months, 3. Ankle plantar flexor spasticity MAS ≥1, 4. Brunnstrom stage ≥3 for lower extremity, 5. Patients who were standing for more than one minute and had a static balance  Cardiac disorder (rhythm / conduction disorder, cardiac pacemaker, ischemic heart disease) 2. The presence of lower extremity fracture, 3. Findings or suspicion of active deep vein thrombosis, 4. A history of deep vein thrombosis and pulmonary embolism, 5. Orthostatic hypotension 6. Resistant hypertension, 7. Peripheral nerve lesions such as polyneuropathy, radiculopathy 8. Active inflammatory, rheumatologic or infectious disease, 9. Having joint contracture, 10. Having a history of panic attacks, 11. Patients with dizziness and balance problems, 12. Patients with not intact skin surface to connect electrodes 13. Patients with communication problems: aphasia, major depression 14. Epilepsy 15. Patients who received botulinum A toxin in the last 6 months
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 0.0-999.0,  Cerebrovascular Accident Participants were eligible for in the study if they had evidence suggesting acute ischemic stroke that lasted for ≤ 4.5 hours  Those Participants were treated with intravenous thrombolytic therapy ((recombinant tissue plasminogen activator (rt-PA))  Those who had hemorrhagic stroke participants presented with acute myocardial infarction, cerebrovascular stroke in the previous three months serious head trauma in the previous three months urinary tract, lung, or gastrointestinal hemorrhage within the three weeks serious trauma or major surgery within the previous two weeks lumbar or arterial puncture at a non-compressible site within one week those received heparin within 48 hours, resulting in an activated partial thromboplastin time greater than the upper limit of normal systolic pressure > 185 mmHg or diastolic pressure > 110 mmHg blood glucose <50 or > 400 mg/dL current use of anticoagulants with an International Normalized Ratio > 1.7 or prothrombin time>15 sec; platelet count < 100,000/mm3
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 40.0-65.0,  Cerebral Stroke Malondialdehyde Oxidative Stress 65 years old Has acute ischemic stroke with an onset of less than 48 hours before hospital admission NIHSS score of less than or equal to 15 Can consume food orally or enterally Has given their consent to be a participant in the study  Renal failure Liver failure Is taking supplements other than his or her main stroke medications Has taken antioxidant supplements in the last 3 months before stroke onset
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  Ischemic Stroke Age over 18 Consent on participation Diagnosed Ischemic Stroke  Active cancer disease Kidney failure Liver failure Pregnancy Breastfeeding
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Acute Pre and Post Operative Pain Any adult patient undergoing surgery in our institution during the study duration able to express pain intensity on NRS  patient to be operated on in the area of the face or eye Patient with altered facial morphology related to a dressing, suture, wound, trauma or oedema on the face patient not compliant or unable to clearly express pain
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 13.0-25.0,  Brain Injuries, Traumatic Concussion, Mild Concussion, Intermediate Concussion, Severe Concussion, Brain For Injured subjects: 1. Having sustained a traumatic closed head injury within 72 hours (3 days) from time of injury at time of BrainScope assessment; 2. GCS 13-15 at time of BrainScope assessment; 3. No hospital admission due to either head injury or collateral injuries for >24 hours. For Matched Controls: 1. GCS 15 at time of BrainScope assessment; 2. No prior history of concussion or TBI in the last year  Previously enrolled in the BrainScope CAS Studies; 2. Current CNS active prescription medications taken daily, with the exception of medications being taken for the treatment of Attention Deficit Disorder (ADD) or Attention Deficit Hyperactivity Disorder (ADHD); 3. Forehead, scalp or skull abnormalities that prevents headset application or EEG data collection; 4. History of brain surgery or neurological disease; 5. Pregnant women; 6. Subjects who do not speak English (non-English speaking parents are allowed to consent so long as translation of the consent form in their native language is available); 7. Acute intoxication; 8. Evidence of illicit drug usage; For Injured subjects: 1. Loss of consciousness ≥ 20 minutes related to the concussion injury; 2. Active fever defined as greater than 100ºF or 37.78ºC at time of BrainScope assessment; 3. Evidence of abnormality visible on Computerized Tomography (CT) of the head related to the traumatic event (Note: neuroimaging is not required for enrollment). For Matched Controls: 1. Any focal neurological signs including aphasia, apraxia, diplopia, facial droop, dysarthria/slurred speech; 2. History of Motor Vehicle Accident (MVA) requiring an Emergency Department visit within the past 1 year
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-60.0,  Acute Ischemic Stroke Aged from 18 to 75 years Suffered from acute hemiparesis/-plegia with at least one symptom of cortical impairment (aphasia, hemianopia, unilateral neglect) or gaze deviation Patients who can be admitted to hospital within an anticipated 5 hours after symptom onset Known onset time of symptom Only mothership admissions Fully autonomous patient (pre-stroke mRS ≤2) Regardless of any neurological improvement between randomization and hospital arrival Immediate availability of the angiosuite at the admission Informed consent  Severe allergy to iodinated contrast agents Ongoing pregnancy Breastfeeding Consent refusal or withdraw Individuals under mandatory legal guardianship or unable to consent and whose relatives oppose the research Non-affiliation to or beneficiary of a social insurance regime Any conditions that could hamper the 3-month outcome recording
Patient description: A 62-year-old African-American man presented with left upper and lower extremity weakness, associated with dark visual spot in right eye, right facial numbness, facial drop and slurred speech. He denied dyspnea, headache, palpitations, chest pain, fever, dizziness, bowel or urinary incontinence, loss of consciousness. His medical history was significant for hypertension, hyperlipidemia and hypothyroidism. He smokes cigarette 1 pack per day for 40 years and alcohol consumption of 5 to 6 beers per week. He is not aware about his family history. He is using Levothyroxine, Atorvastatin and HTCZ. His vital signs were stable in the primary evaluation. Left-sided facial droop, dysarthria, and left-sided hemiplegia were seen in the physical exam. His National Institutes of Health Stroke Scale (NIHSS) score was calculated as 7. Initial CT angiogram of head and neck reported no acute intracranial findings. Intravenous recombinant tissue plasminogen activator (t-PA) was administered as well as high-dose statin therapy. The patient was admitted to the intensive care unit to be monitored for 24 hours. MRI of the head revealed an acute 1.7-cm infarct of the right periventricular white matter and posterior right basal ganglia.

Clinical trial eligibility criteria: eligible ages (years): 18.0-80.0,  Insomnia Male or female aged between 18 and 80 years old Registered at one of the participating spas, for a psychosomatic spa treatment scheduled for the next 12 months, but within a period of more than 16 weeks ISI score ≥ 8 on the pre-selection questionnaire Person with a persistent insomnia disorder, with or without comorbidities, according to DSM 5 Owning or having access to a computer / tablet or smartphone and to an internet connection Affiliated to a national health service Having given written informed consent to participate in the trial  Strong suspicion of obstructive sleep apnea (OSA) syndrome on the STOP-BANG questionnaire and restless legs syndrome on the RLS screening questionnaire Having started antidepressant treatment in the last 2 months or whose treatment dose has been increased in the last 2 months Having started treatment with anxiolytic, hypnotic or neuroleptic in the last month or whose dosage of treatment has been increased in the last month Having carried out a spa treatment in the last 6 months, whatever the specialty Registered to follow a complementary program for insomnia disorders during the planned spa treatment Pregnant or lactating women Major under guardianship or curatorship Night and shift-workers Having undertaken trans-meridian travel (± 3H) in the previous 1 month